Sistema endocrino y corazón: una revisión
Tóm tắt
Từ khóa
Tài liệu tham khảo
Biller, 1999, Guidelines for the diagnosis and treatment of hyperprolactinemia, J Reprod Med., 44, 1075
Casanueva, 2006, Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas, Clin Endocrinol (Oxf)., 65, 265, 10.1111/j.1365-2265.2006.02562.x
Zanettini, 2007, Valvular heart disease and the use of dopamine agonists for Parkinson's disease, N Engl J Med., 356, 39, 10.1056/NEJMoa054830
Schade, 2007, Dopamine agonists and the risk of cardiac-valve regurgitation, N Engl J Med., 356, 29, 10.1056/NEJMoa062222
Bogazzi, 2008, Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies, J Endocrinol Invest., 31, 1119, 10.1007/BF03345662
Tan, 2010, Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinemia, Clin Endocrinol (Oxf)., 73, 369, 10.1111/j.1365-2265.2010.03827.x
Valassi, 2010, Potential cardiac valve effects of dopamine agonists in hyperprolactinemia, J Clin Endocrinol Metab., 95, 1025, 10.1210/jc.2009-2095
Hilfiker-Kleiner, 2007, A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy, Cell., 128, 589, 10.1016/j.cell.2006.12.036
Sliwa, 2010, Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy, Eur J Heart Fail., 12, 767, 10.1093/eurjhf/hfq120
Lu, 2001, Demonstration of direct effects of growth hormone on neonatal cardiomyocytes, J Biol Chem., 276, 22892, 10.1074/jbc.M011647200
McCallum, 2002, Growth hormone deficiency and vascular risk, Clin Endocrinol (Oxf)., 57, 11, 10.1046/j.1365-2265.2002.01559.x
Chanson, 2009, Pituitary tumours: acromegaly, Best Pract Res Clin Endocrinol Metab., 23, 555, 10.1016/j.beem.2009.05.010
Cook, 2004, AACE medical guidelines for clinical practice for the diagnosis and treatment of acromegaly, Endocr Pract., 10, 213, 10.4158/EP.10.3.213
Molitch, 2006, Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab., 91, 1621, 10.1210/jc.2005-2227
Cook, 2009, American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients—2009 update, Endocr Pract., 15, 1, 10.4158/EP.15.S2.1
Attanasio, 2010, Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement, J Clin Endocrinol Metab., 95, 74, 10.1210/jc.2009-1326
Abdu, 2001, Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities, Clin Endocrinol (Oxf)., 55, 209, 10.1046/j.1365-2265.2001.01320.x
Colao, 2008, The GH-IGF-1 axis and the cardiovascular system: clinical implications, Clin Endocrinol (Oxf)., 69, 347, 10.1111/j.1365-2265.2008.03292.x
Markussis, 1992, Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults, Lancet., 340, 1188, 10.1016/0140-6736(92)92892-J
Hodis, 1998, The role of carotid arterial intima-media thickness in predicting clinical coronary events, Ann Intern Med., 128, 262, 10.7326/0003-4819-128-4-199802150-00002
Bengtsson, 1993, Treatment of adults with growth hormone (GH) deficiency with recombinant human GH, J Clin Endocrinol Metab., 76, 309, 10.1210/jc.76.2.309
Maison, 2004, Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials, J Clin Endocrinol Metab., 89, 2192, 10.1210/jc.2003-030840
Smith, 2002, Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study, Clin Endocrinol (Oxf)., 56, 493, 10.1046/j.1365-2265.2002.01514.x
Colao, 2006, Beginning to end: cardiovascular implications of growth hormone deficiency (GHD) and GH therapy, Growth Horm IGF Res., 16, S41, 10.1016/j.ghir.2006.03.006
Colao, 2001, Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency, J Clin Endocrinol Metab., 86, 1874, 10.1210/jc.86.5.1874
Jallad, 2003, Effects of growth hormone replacement therapy on metabolic and cardiac parameters, in adult patients with childhood-onset growth hormone deficiency, Growth Horm IGF Res., 13, 81, 10.1016/S1096-6374(03)00006-6
Colao, 2004, The heart: an end-organ of GH action, Eur J Endocrinol., 151, S93, 10.1530/eje.0.151S093
Maison, 2003, Cardiac effects of growth hormone in adults with growth hormone deficiency: a metaanalysis, Circulation., 108, 2648, 10.1161/01.CIR.0000100720.01867.1D
Bengtsson, 1988, Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984, Acta Med Scand., 223, 327, 10.1111/j.0954-6820.1988.tb15881.x
Trainer, 2000, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant, N Engl J Med., 342, 1171, 10.1056/NEJM200004203421604
Castellano, 2009, The GH/IGF-1 axis and heart failure, Current Cardiol Rev., 5, 203, 10.2174/157340309788970306
Berg, 2010, Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control, J Clin Endocrinol Metab., 95, 3648, 10.1210/jc.2009-2570
Mestron, 2004, Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry, Eur J Endocrinol., 151, 439, 10.1530/eje.0.1510439
Damjanovic, 2002, High output heart failure in patients with newly diagnosed acromegaly, Am J Med., 112, 610, 10.1016/S0002-9343(02)01094-X
Minniti, 2001, Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients, Clin Endocrinol (Oxf)., 55, 307, 10.1046/j.1365-2265.2001.01343.x
Maison, 2007, Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis, J Clin Endocrinol Metab., 92, 1743, 10.1210/jc.2006-2547
Bruch, 2002, Impact of disease activity on left ventricular performance in patients with acromegaly, Am Heart J., 144, 538, 10.1067/mhj.2002.123572
Pereira, 2004, Increased prevalence of regurgitant valvular heart disease in acromegaly, J Clin Endocrinol Metab., 89, 71, 10.1210/jc.2003-030849
Colao, 2003, High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study, J Clin Endocrinol Metab., 88, 3196, 10.1210/jc.2002-021099
Rodrigues, 1989, Subclinical cardiac dysfunction in acromegaly: evidence for a specific disease of heart muscle, Br Heart J., 62, 185, 10.1136/hrt.62.3.185
Herrmann, 2001, Occurrence of ventricular late potentials in patients with active acromegaly, Clin Endocrinol (Oxf)., 55, 201, 10.1046/j.1365-2265.2001.01319.x
Kahaly, 1992, Arrhythmia profile in acromegaly, Eur Heart J., 13, 51, 10.1093/oxfordjournals.eurheartj.a060047
Fatti, 2006, Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients, Clin Endocrinol (Oxf)., 65, 626, 10.1111/j.1365-2265.2006.02639.x
Boscaro, 2009, Approach to the patient with possible Cushing's syndrome, J Clin Endocrinol Metab., 94, 3121, 10.1210/jc.2009-0612
Lindholm, 2001, Incidence and late prognosis of Cushing's syndrome: a population-based study, J Clin Endocrinol Metab., 86, 117, 10.1210/jc.86.1.117
Nieman, 2008, The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab., 93, 1526, 10.1210/jc.2008-0125
Guignat, 2010, The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline: commentary from a European perspective, Eur J Endocrinol., 163, 9, 10.1530/EJE-09-0627
Stewart, 2009, Rationale for treatment and therapeutic options in Cushing's disease, Best Pract Res Clin Endocrinol Metab., S15, 10.1016/S1521-690X(09)70004-1
Biller, 2008, Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement, J Clin Endocrinol Metab., 93, 2454, 10.1210/jc.2007-2734
Faggiano, 2003, Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1year after disease remission, J Clin Endocrinol Metab., 88, 2527, 10.1210/jc.2002-021558
Fallo, 2009, Should we evaluate for cardiovascular disease in patients with Cushing's syndrome?, Clin Endocrinol (Oxf)., 71, 768, 10.1111/j.1365-2265.2009.03610.x
Whitworth, 2000, Cushing, cortisol, and cardiovascular disease, Hypertension., 36, 912, 10.1161/01.HYP.36.5.912
Whitworth, 2005, Cardiovascular consequences of cortisol excess, Vasc Health Risk Manag., 1, 291, 10.2147/vhrm.2005.1.4.291
Magiakou, 2006, Hypertension in Cushing's Syndrome, Best Pract Res Clin Endocrinol Metab., 20, 467, 10.1016/j.beem.2006.07.006
Fernández-Real, 2003, Insulin resistance and chronic cardiovascular inflammatory syndrome, Endocr Rev., 24, 278, 10.1210/er.2002-0010
Ambrosi, 2000, Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma, Exp Clin Endocrinol Diabetes., 108, 294, 10.1055/s-2000-8000
Boscaro, 2002, Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome, J Clin Endocrinol Metab., 87, 3662, 10.1210/jc.87.8.3662
Arnaldi, 2004, Cardiovascular risk in Cushing's syndrome, Pituitary., 7, 253, 10.1007/s11102-005-1172-7
Muiesan, 2003, Left ventricular-structural and functional characteristics in Cushing's syndrome, J Am Coll Cardiol., 41, 2275, 10.1016/S0735-1097(03)00493-5
Pereria, 2010, Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome, Eur J Endocrinol., 162, 331, 10.1530/EJE-09-0621
Hollowell, 2002, Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III), J Clin Endocrinol Metab., 87, 489, 10.1210/jc.87.2.489
Sawin, 1991, Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism, Arch Intern Med., 15, 165, 10.1001/archinte.151.1.165
Sawin, 1985, The aging thyroid. Thyroid deficiency and the Framingham Study, Arch Intern Med., 145, 1386, 10.1001/archinte.145.8.1386
Biondi, 2008, The clinical significance of subclinical thyroid dysfunction, Endocr Rev., 29, 76, 10.1210/er.2006-0043
Surks, 2004, Subclinical thyroid disease: scientific review and guidelines for diagnosis and management, JAMA., 291, 228, 10.1001/jama.291.2.228
Davis, 2002, Nongenomic actions of thyroid hormone on the heart, Thyroid., 12, 459, 10.1089/105072502760143827
Napoli, 2001, Impact of hyperthyroidism and its correction on vascular reactivity in humans, Circulation., 104, 3076, 10.1161/hc5001.100621
Ojamaa, 1996, Acute effects of thyroid hormone on vascular smooth muscle, Thyroid., 6, 505, 10.1089/thy.1996.6.505
Fish, 2005, The blood in thyrotoxicosis, 595
Biondi, 2002, Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism, J Clin Endocrinol Metab., 87, 968, 10.1210/jc.87.3.968
Klein, 2007, Thyroid disease and the heart, Circulation., 116, 1725, 10.1161/CIRCULATIONAHA.106.678326
Danzi, 2004, Thyroid hormone and the cardiovascular system, Minerva Endocrinol., 29, 139
Danzi, 2003, Thyroid hormone and blood pressure regulation, Curr Hypertens Rep., 5, 513, 10.1007/s11906-003-0060-7
Prisant, 2006, Hyperthyroidism: a secondary cause of isolated systolic hypertension, J Clin Hypertens., 8, 596, 10.1111/j.1524-6175.2006.05180.x
Dorr, 2005, The association of thyroid function with cardiac mass and left ventricular hypertrophy, J Clin Endocrinol Metab., 90, 673, 10.1210/jc.2004-1554
Petretta, 2001, Cardiovasular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism, Eur J Endocrinol., 145, 691, 10.1530/eje.0.1450691
Mintz, 1991, Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment, J Clin Endocrinol Metab., 73, 146, 10.1210/jcem-73-1-146
Osman, 2007, Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study, J Am Coll Cardiol., 49, 71, 10.1016/j.jacc.2006.08.042
Northcote, 1986, Continuous 24-hour electrocardiography in thyrotoxicosis before and after treatment, Am Heart J., 112, 339, 10.1016/0002-8703(86)90272-3
Osman, 2002, Clinical review 142: cardiac dysrhythmias and thyroid dysfunction: the hidden menace?, J Clin Endocrinol Metab., 87, 963, 10.1210/jc.87.3.963
Sawin, 1994, Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons, N Engl J Med., 331, 1249, 10.1056/NEJM199411103311901
Osman, 2002, Hyperthyroidism and cardiovascular morbidity and mortality, Thyroid., 12, 483, 10.1089/105072502760143854
Gharib, 2005, Subclinical thyroid dysfunction: a joint statement from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society, J Clin Endocrinol Metab., 90, 581, 10.1210/jc.2004-1231
Klein, 2005, Endocrine disorders and cardiovascular disease, 2051
Klein, 2001, Thyroid hormone and the cardiovascular system, N Engl J Med., 344, 501, 10.1056/NEJM200102153440707
Biondi, 2004, Hypothyroidism as a risk factor for cardiovascular disease, Endocrine., 24, 1, 10.1385/ENDO:24:1:001
Cappola, 2003, Hypothyroidsm and atherosclerosis, J Clin Endocrinol Metab., 88, 2438, 10.1210/jc.2003-030398
Pearce, 2004, Hypothyroidism and dyslipidemia: modern concepts and approaches, Curr Cardiol Rep., 6, 451, 10.1007/s11886-004-0054-3
Wang, 2010, Hypothyroid cardiac tamponade: clinical features, electrocardiography, pericardial fluid and management, Am J Med Sci., 340, 276, 10.1097/MAJ.0b013e3181e664c6
Wald, 2006, ECG manifestations of selected metabolic and endocrine disorders, Emerg Med Clin North Am., 24, 145, 10.1016/j.emc.2005.08.010
Bogazzi, 2010, Approach to the patient with amiodarone-induced thyrotoxicosis, J Clin Endocrinol (Oxf)., 95, 2529, 10.1210/jc.2010-0180
Ascheim, 2002, Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothyronine state, Thyroid., 12, 511, 10.1089/105072502760143908
Galli, 2010, The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence, Heart Fail Rev., 15, 155, 10.1007/s10741-008-9126-6
Gerdes, 2010, Thyroid replacement therapy and heart failure, Circulation., 122, 385, 10.1161/CIRCULATIONAHA.109.917922
Brown, 1994, Homeostatic mechanisms regulating extracellular and intracellular calcium metabolism, 15
Golden, 2009, Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review, J Clin Endocrinol Metab., 94, 1853, 10.1210/jc.2008-2291
Bilezikian, 2009, Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop, J Clin Endocrinol Metab., 94, 335, 10.1210/jc.2008-1763
Silverberg, 2009, Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop, J Clin Endocrinol Metab., 94, 351, 10.1210/jc.2008-1760
Procopio, 2002, The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed Type 2 diabetes mellitus in primary hyperparathyroidism, Diabet Med., 19, 958, 10.1046/j.1464-5491.2002.00809.x
Nainby-Luxmoore, 1982, A case-comparison study of hypertension and hyperparathyroidism, J Clin Endocrinol Metab., 55, 303, 10.1210/jcem-55-2-303
Taylor, 2008, Parathyroid hormone and the risk of incident hypertension, J Hypertension., 26, 1390, 10.1097/HJH.0b013e3282ffb43b
Heylinger, 2009, Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hypertension, Surgery., 146, 1042, 10.1016/j.surg.2009.09.024
Bollerslev, 2009, Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism, J Clin Endocrinol Metab., 94, 2255, 10.1210/jc.2008-2742
Kautzky-Willer, 1992, Insulin secretion, insulin sensitivity and hepatic insulin extraction in primary hyperparathyroidism before and after surgery, Clin Endocrinol (Oxf)., 37, 147, 10.1111/j.1365-2265.1992.tb02299.x
Ayturk, 2006, Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism, J Clin Endocrinol Metab., 91, 4260, 10.1210/jc.2005-2825
Walker, 2009, Carotid vascular abnormalities in primary hyperparathyroidism, J Clin Endocrinol Metab., 94, 3849, 10.1210/jc.2009-1086
Andersson, 2004, Primary hyperparathyroidism and heart disease—a review, Eur Heart J., 25, 1776, 10.1016/j.ehj.2004.07.010
Stefenelli, 1997, Cardiac abnormalities in patients with primary hyperparathyroidism: Implications for follow-up, J Clin Endocrinol Metab., 82, 106, 10.1210/jc.82.1.106
Vázquez-Díaz, 2009, Reversible changes of electrocardiographic abnormalities after parathyroidectomy in patients with primary hyperparathyroidism, Cardiol J., 16, 241
Rosenqvist, 1992, Cardiac conduction in patients with hypercalcaemia due to primary hyperparathyroidism, Clin Endocrinol (Oxf)., 37, 29, 10.1111/j.1365-2265.1992.tb02279.x
Curione, 2007, Increased risk of cardiac death in primary hyperparathyroidism: what is a role of electrical instability?, Int J Cardiol., 121, 200, 10.1016/j.ijcard.2006.08.072
Shoback, 2008, Clinical practice. Hypoparathyroidism, N Engl J Med., 359, 391, 10.1056/NEJMcp0803050
Cooper, 2008, Diagnosis and management of hypocalcaemia, BMJ., 336, 1298, 10.1136/bmj.39582.589433.BE
Fisher, 2001, Hypocalcemic cardiomyopathy: the relationship between myocardial damage, left ventricular function, calcium and ECG changes in a patient with idiopathic hypocalcaemia, Eur J Heart Fail., 3, 373, 10.1016/S1388-9842(01)00125-8
Kazmi, 2007, Reversible congestive heart failure related to profound hypocalcemia secondary to hypoparathyroidism, Am J Med Sci., 333, 226, 10.1097/MAJ.0b013e318039b9c6
Suzuki, 1998, Hypocalcemic heart failure: a reversible form of heart muscle disease, Clin Cardiol., 21, 227, 10.1002/clc.4960210319
Avsar, 2004, A rare cause of reversible dilated cardiomyopathy: hypocalcemia, Echocardiography., 21, 609, 10.1111/j.0742-2822.2004.03149.x
RuDusky, 2001, ECG abnormalities associated with hypocalcemia, Chest., 119, 668, 10.1378/chest.119.2.668-a
Lehmann, 2000, ECG changes in a 25-year-old woman with hypocalcemia due to hypoparathyroidism, Chest., 118, 260, 10.1378/chest.118.1.260
Whaley-Connell, 2010, Aldosterone: role in the cardiometabolic syndrome and resistant hypertension, Prog Cardiovasc Dis., 52, 401, 10.1016/j.pcad.2009.12.004
Funder, 2008, Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab., 93, 3266, 10.1210/jc.2008-0104
Young, 2002, Mineralocorticoid receptros and pathophysiological roles for aldosterone in the cardiovascular system, J Hypertens., 20, 1465, 10.1097/00004872-200208000-00002
Young, 2007, Primary aldosteronism: renaissance of a syndrome, Clin Endocrinol (Oxf)., 66, 607, 10.1111/j.1365-2265.2007.02775.x
Conn, 1965, Hypertension, the potassium ion and impaired carbohydrate tolerance, N Engl J Med., 273, 1135, 10.1056/NEJM196511182732106
Galetta, 2009, Cardiac remodeling in patients with primary aldosteronism, J Endocrinol Invest., 32, 739, 10.1007/BF03346529
White, 2003, Aldosterone: direct effects on and production by the heart, J Clin Endocrinol Metab., 88, 2283, 10.1210/jc.2003-030373
Stowasser, 2001, New perspectives on the role of aldosterone excess in cardiovascular disease, Clin Exp Pharmacol Physiol., 28, 783, 10.1046/j.1440-1681.2001.03523.x
Matsumura, 2006, Role of aldosterone in left ventricular hypertrophy in hypertension, Am J Hypertens., 19, 13, 10.1016/j.amjhyper.2005.05.013
Okoshi, 2004, Aldosterone directly stimulates cardiac myocyte hypertrophy, J Card Fail., 10, 511, 10.1016/j.cardfail.2004.03.002
Rizzoni, 2006, Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism, J Clin Endocrinol Metab., 91, 2638, 10.1210/jc.2006-0101
Lijnen, 2000, Induction of cardiac fibrosis by aldosterone, J Mol Cell Cardiol., 32, 865, 10.1006/jmcc.2000.1129
Catena, 2007, Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism, Hypertension., 50, 911, 10.1161/HYPERTENSIONAHA.107.095448
Martínez, 2010, Aldosterone inhibition and cardiovascular protection: more important than it once appeared, Cardiovasc Drugs Ther., 24, 345, 10.1007/s10557-010-6256-6
Modena, 2001, Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction, Am Heart J., 141, 41, 10.1067/mhj.2001.111258
Zannad, 2001, Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship, Hypertension., 38, 1227, 10.1161/hy1101.099484
Ezekowitz, 2009, Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials, Eur Heart J., 30, 469, 10.1093/eurheartj/ehn543
Piit, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med., 341, 709, 10.1056/NEJM199909023411001
Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med., 348, 1309, 10.1056/NEJMoa030207
Udelson, 2010, Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction, Circ Heart Fail., 3, 347, 10.1161/CIRCHEARTFAILURE.109.906909
Young, 2007, Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism, Rev Endocr Metab Disord., 8, 309, 10.1007/s11154-007-9055-z
Pacak, 2007, Preoperative management of the pheochromocytoma patient, J Clin Endocrinol Metab., 92, 4069, 10.1210/jc.2007-1720
Zelinka, 2005, Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients, J Hypertens., 23, 2033, 10.1097/01.hjh.0000185714.60788.52
Plouin, 1997, Tumor recurrence and hypertension persistence after successful pheochromocytoma operation, Hypertension., 29, 1133, 10.1161/01.HYP.29.5.1133
Galetta, 2010, Cardiovascular complications in patients with pheochromocytoma: a mini-review, Biomed Pharmacother., 64, 505, 10.1016/j.biopha.2009.09.014
Bernini, 2008, Normalization of catecholamine production following resection of phaeochromocytoma positively influences carotid vascular remodeling, Eur J Endocrinol., 159, 137, 10.1530/EJE-08-0126